Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 48, 4171-4178, August 1, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peraino, C.
Right arrow Articles by Maronpot, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peraino, C.
Right arrow Articles by Maronpot, R. R.

Comparative Developmental and Phenotypic Properties of Altered Hepatocyte Foci and Hepatic Tumors in Rats1

Carl Peraino2, Bruce A. Carnes, Fred J. Stevens, Everett F. Staffeldt, John J. Russell, Aldona Prapuolenis, Jeanne A. Blomquist, Stan D. Vesselinovitch and Robert R. Maronpot

Biological, Environmental, and Medical Research Division, Argonne National Laboratory, Argonne, Illinois 60439 [C. P., B. A. C., F. J. S., E. F. S., J. J. R., A. P., J. A. B.]; Departments of Radiology and Pathology, The University of Chicago, Chicago, Illinois 60637 [S. D. V.]; and Department of Pathology, The National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709 [R. R. M.]

Previous investigations in this laboratory have provided evidence that histochemically detectable altered hepatocyte foci and hepatic tumors appearing in rats given a single neonatal treatment with a low dose of carcinogen followed by chronic dietary phenobarbital administration are developmentally independent. The present investigation further evaluates developmental relationships among these lesions. Altered hepatocyte foci were divided into two subclasses consisting of foci that were detectable by histochemical as well as by hematoxylin-eosin staining [designated hist(+)/morph(+) foci] and those foci that were detectable solely by histochemical staining [designated hist(+)/morph(-) foci]. The developmental and phenotypic properties of the hist(+)/morph(-) foci, hist(+)/morph(+) foci, and hepatic tumors were compared in rats initiated once neonatally with different doses of diethylnitrosamine and promoted with dietary phenobarbital from weaning.

The morph(+) and morph(-) lesion subclasses were distinguishable on the basis of several developmental characteristics. Hist(+)/morph(+) foci were present at low frequency until at least 150 days after initiation. Although the development of hist(+)/morph(-) foci was essentially complete at that point, the rate of appearance of hist(+)/morph(+) increased significantly. The diethylnitrosamine dose response of the hist(+)/morph(+) foci followed the histochemical marker patterns of the tumor lesion class more closely than that of the hist(+)/morph(-) group. The rates of expression of the hist(+)/morph(+) foci increased with the increasing level of histochemical complexity, whereas the rates of expression of the hist(+)/morph(-) foci groups were inversely correlated to their complexity level. Although the average focus size or diameter in the hist(+)/morph(+) groups was greater than that of the hist(+)/morph(-) foci, the focus growth rates of morph(+) and morph(-) subsets matched for histochemical phenotype were comparable. The complexity level and individual marker distribution patterns for the hist(+)/morph(+) focus class were more similar to tumor patterns than to the distribution patterns of the hist(+)/morph(-) lesion class.

The results suggest the following. (a) The development of lesion classes with successively greater deviation from normalcy does not occur via lineal progression from less to more deviated forms within a given lesion class. The three lesion classes appear to develop independently, with the developmental characteristics of each lesion class determined at the time of initiation. (b) The marked phenotypic diversity among lesions within each of the three lesion classes, as denoted by frequencies and combinations of histochemical markers per lesion, results from pleiotropic effects of the carcinogen-mediated initiation event(s) responsible for the generation of each lesion class rather than from a broad collection of primary initiation events. (c) Although none of the markers has been shown to be directly linked to the mechanism of neoplasia, the systematic changes in their response patterns across the three classes of lesions (which show increasing deviation from normal cellular morphology) support the relevance of marker behavior as an index of carcinogen-induced changes in the expression of gene families involved in the control of cellular differentiation.

1 Supported by the United States Department of Energy, Office of Health and Environmental Research, under Contract W-31-109-ENG-38, and by the National Toxicology Program under Interagency Agreement Y01-ES-20091.

2 To whom requests for reprints should be addressed.

Received 12/21/87. Revised 3/21/88. Accepted 3/31/88.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1988 by the American Association for Cancer Research.